AI Article Synopsis
- - The study explored the links between refeeding syndrome and hypophosphataemia in extremely low birthweight babies (under 1000g), and their potential effects on death or neurodisability at 2 years of age.
- - Conducted as a secondary cohort analysis within the ProVIDe trial, the research involved 352 ELBW infants born from 2014 to 2018 in New Zealand, analyzing their serum biochemistry during the first week after birth.
- - Results indicated that refeeding syndrome and hypophosphataemia significantly increased the likelihood of death or neurodisability, highlighting the need for vigilant monitoring and intervention regarding phosphate levels in these vulnerable infants.
Article Abstract
Objective: To investigate in extremely low birthweight (ELBW; <1000 g) babies the associations between refeeding syndrome (serum phosphate <1.4 mmol·L and serum total calcium>2.8 mmol·L) and hypophosphataemia in the first week and death or neurodisability at 2 years' corrected age (CA).
Design: Secondary cohort analysis of the ProVIDe trial participants with serum biochemistry within 7 days of birth. At 2 years' CA, neurodisability was assessed by Bayley Scales of Infant Development Edition III and neurological examination. Associations between neurodisability and other variables were analysed using t-tests and logistic regression adjusted for sex and smallness-for-gestational age.
Setting: Six tertiary neonatal intensive care units (NICUs) in New Zealand.
Participants: 352 ELBW babies born between 29 April 2014 and 30 October 2018.
Main Outcome Measure: Death or neurodisability at 2 years' CA.
Results: Fifty-nine babies died, two after discharge from the NICU. Of the 336 babies who survived to 2 years' CA, 277 had neurodevelopmental assessment and 107 (39%) had a neurodisability. Death or neurodisability was more likely in babies who had refeeding syndrome (aOR 1.96 (95% CI 1.09 to 3.53), p=0.02) and in babies who had hypophosphataemia (aOR 1.74 (95% CI 1.09 to 2.79), p=0.02). Hypophosphataemia was associated with increased risk of death (aOR 2.07 (95% CI 1.09 to 3.95), p=0.03)) and severe hypophosphataemia (<0.9 mmol·L) with increased risk of death (aOR 2.67 (95% CI 1.41 to 5.00), p=0.002) and neurodisability (aOR 2.31 (95% CI 1.22 to 4.35), p=0.01).
Conclusions: In ELBW babies, refeeding syndrome and hypophosphataemia in the first week are associated with death or neurodisability. Until optimal phosphate requirements are determined through further research, monitoring for hypophosphataemia and mitigation strategies are indicated.
Trial Registration Number: ACTRN12612001084875.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/archdischild-2024-327029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!